Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Apr 1, 2025
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe
Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus
Read more at globenewswire.comNASDAQ:MYNZ (4/25/2025, 2:03:44 PM)
3.42
+0.22 (+6.87%)
Find more stocks in the Stock Screener
